| Literature DB >> 17970884 |
M Rosenbach1, Victoria P Werth.
Abstract
Thalidomide was first introduced in the 1950s, and its widespread use led to thousands of birth defects through the 1960s; it was quickly withdrawn from the market. A fortuitous discovery identified during treatment of patients with erythema nodosum leprosum led to the recognition of the potent anti-inflammatory effects of thalidomide and a resurgence of interest in the drug. In the ensuing decades, thalidomide has been recognized as a potential treatment option in a number of dermatologic conditions. This article reviews the history, pharmacology, mechanisms of action, and off-label uses of thalidomide and serves as a guide for dermatologists to comfortably and safely institute and monitor thalidomide to patients with cutaneous disease.Entities:
Mesh:
Substances:
Year: 2007 PMID: 17970884 DOI: 10.1111/j.1529-8019.2007.00132.x
Source DB: PubMed Journal: Dermatol Ther ISSN: 1396-0296 Impact factor: 2.851